A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
Novartis
Fujian Cancer Hospital
First People's Hospital of Hangzhou
Shanghai Chest Hospital
First People's Hospital of Hangzhou
National Cancer Institute (NCI)
Massachusetts General Hospital
National Cancer Center, Korea
Swiss Cancer Institute
National Cancer Institute (NCI)